Literature DB >> 9139753

Autoimmune disorders, physical activity, and training, with particular reference to rheumatoid arthritis.

R J Shephard1, P N Shek.   

Abstract

Rheumatoid arthritis arises from a reaction of the immune system to normal body components, sometimes triggered by bacterial or viral infection. The synovia of affected joints are infiltrated by CD4+, CD19-, and plasma cells. The synovial fluid shows a sterile inflammation, with high neutrophil counts and increased concentrations of proinflammatory cytokines (particularly IL-1, IL-8, TNF-alpha and JFN-gamma). The plasma shows increased CD4+ counts and a pro-inflammatory shift in T cell populations with high titers of rheumatoid factors. Traditional treatment has included rest of the affected part, which can cause a reduction of physical condition. However, exercise induces changes in circulating immune function (including a decrease of CD4+ count) that would appear helpful in regulating inflammation. Further, there is evidence that patients can tolerate a program of regular moderate aerobic exercise. Moreover, empirical data suggest that such a prescription substantially enhances physical performance, without exacerbating either clinical or immunological markers of the disease process.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9139753

Source DB:  PubMed          Journal:  Exerc Immunol Rev        ISSN: 1077-5552            Impact factor:   6.308


  3 in total

1.  Physical activity and health related physical fitness in children with juvenile idiopathic arthritis.

Authors:  T Takken; J van der Net; W Kuis; P J M Helders
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

2.  Impact of physical activity on inflammation: effects on cardiovascular disease risk and other inflammatory conditions.

Authors:  Sibel Ertek; Arrigo Cicero
Journal:  Arch Med Sci       Date:  2012-11-07       Impact factor: 3.318

Review 3.  The Impact of Exercise in Rodent Models of Chronic Pain.

Authors:  Mark Henry Pitcher
Journal:  Curr Osteoporos Rep       Date:  2018-08       Impact factor: 5.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.